Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium

Vaccine

Volumn 30, Issue 3, 2012, Pages 675-684

  Bilcke, Joke ^a   Marais, Christiaan ^a   Ogunjimi, Benson ^a   Willem, Lander ^a   Hens, Niel ^a,b   Beutels, Philippe ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Cost utility; Illness; Shingles; Uncertainty; Zona

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BELGIUM; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; FEMALE; GERIATRICS; HEALTH SURVEY; HERPES VIRUS; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; VACCINATION;

AGED; AGED, 80 AND OVER; BELGIUM; COST-BENEFIT ANALYSIS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; VACCINATION;

EID: 84355166381     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.036     Document Type: Article

References (38)

1. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
2. Wareham D.W., Breuer J. Herpes zoster. BMJ 2007, 334(7605):1211-1215.
3. Drolet M., Brisson M., Levin M.J., Schmader K.E., Oxman M.N., Johnson R.W., et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010, 26(8):656-666.
4. Helgason S., Petursson G., Gudmundsson S., Sigurdsson J.A. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000, 321(7264):794-796.
5. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
6. Annemans L., Bresse X., Gobbo C., Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 2010, 13(3):537-551.
7. Bilcke J, Ogunjimi B, Marais C, De Smet F, Callens M, Callaert K, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect, in press.
8. Brisson M., Pellissier J.M., Camden S., Quach C., De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccines 2008, 4(3):238-245.
9. Edmunds W.J., Brisson M., Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19(23-24):3076-3090.
10. Hornberger J., Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006, 145(5):317-325.
11. Najafzadeh M., Marra C.A., Galanis E., Patrick D.M. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009, 27(12):991-1004.
12. Pellissier J.M., Brisson M., Levin M.J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007, 25(49):8326-8337.
13. Rothberg M.B., Virapongse A., Smith K.J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44(10):1280-1288.
14. van Hoek A.J., Gay N., Melegaro A., Opstelten W., Edmunds W.J. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009, 27(9):1454-1467.
15. van Lier A., van Hoek A.J., Opstelten W., Boot H.J., de Melker H.E. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 2010, 10:237.
16. Ihaka R., Gentleman R.R. A language for data analysis and graphics. J Comput Graphical Stat 1996, 5(3):299-314.
17. Barendregt J.J. The half-cycle correction: banish rather than explain it. Med Decis Making 2009, 29(4):500-502.
18. Cleemput I, Van Wilder P, Vrijens F, Huybrechts M, Ramaekers D. Guidelines for pharmacoeconomic evaluations in Belgium. KCE reports 78C; 2008. http://kce.fgov.be/index_en.aspx%3FSGREF=5223%26CREF=11069.
19. Wood S.N. Generalized additive models: a introduction with R 2006, CRC/Chapman & Hall.
20. Schmader K., Oxman M., Levin M., Betts R.F., Morrison V.A., Gelb L.D., et al. Persistence of zoster vaccine efficacy 2008, ICAAC/IDSA, Durham.
21. Ahnn S. FDA statistical review and evaluation: zostavax 2005, Document for the Vaccines and Related Biological Products Advisory Committee.
22. Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine 2011, doi:10.1016/j.vaccine.2011.09.079.
23. Oxman M.N., Levin M.J. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008, 197(Suppl. 2):S228-S236.
24. Chang M.N., Guess H.A., Heyse J.F. Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med 1994, 13(18):1807-1814.
25. Coplan P.M., Schmader K., Nikas A., Chan I.S., Choo P., Levin M.J., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5(6):344-356.
26. Scott F.T., Johnson R.W., Leedham-Green M., Davies E., Edmunds W.J., Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 2006, 24(9):1308-1314.
27. Scott F.T., Leedham-Green M.E., Barrett-Muir W.Y., Hawrami K., Gallagher W.J., Johnson R., et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003, 70(Suppl. 1):S24-S30.
28. Drolet M., Brisson M., Schmader K., Levin M., Johnson R., Oxman M., et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010, 11(11):1211-1221.
29. Drolet M., Brisson M., Schmader K.E., Levin M.J., Johnson R., Oxman M.N., et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010, 182(16):1731-1736.
30. Bilcke J., Beutels P., Brisson M., Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011, 31(4):675-692.
31. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001, 10(8):751-774.
32. Brisson M., Gay N.J., Edmunds W.J., Andrews N.J. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002, 20(19-20):2500-2507.
33. Bilcke J, Marais C, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, et al. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. KCE reports 151; 2011. http://www.kce.fgov.be/index_en.aspx%3FSGREF=5211%26CREF=18897.
34. Oster G., Harding G., Dukes E., Edelsberg J., Cleary P.D. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005, 6(6):356-363.
35. Bala M.V., Wood L.L., Zarkin G.A., Norton E.C., Gafni A., O'Brien B. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998, 51(8):667-676.
36. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005, 20(8):748-753.
37. Briggs A., Claxton K., Sculpher M. Decision modelling for health economic evaluation 2006, Oxford University Press, New York.
38. Bilcke J., Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27(4):281-297.